[4] [5] For weight management, NICE technology appraisals (TA875 for Wegovy, TA664 for Saxenda) specify these treatments should be used within specialist weight management services (tier 3 or 4), with specific eligibility criteria, time-limited use, and defined stopping rules
For example, increased activity of the endocannabinoid system does not influence GLP-1 concentrations 74,75 , and the effects of CB1 receptor antagonists on appetite, food intake, and weight are not mediated by GLP-1 76,77
Semaglutide has a delicate molecular structure thats sensitive to heat, and once its altered, the medication may not work as intended
It is also contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [16]
For instance, the contribution of lipid metabolism, particularly PUFA biosynthesis, to ferroptosis sensitivity in PDAC is not fully defined
Handb Exp Pharmacol 112:4578 Acknowledgements B